takhzyro
takeda pharmaceuticals international ag ireland branch - lanadelumab - angioödeem, pärilik - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.
promethazine caduceus õhukese polümeerikattega tablett
caduceus pharma ltd. - prometasiin - õhukese polümeerikattega tablett - 25mg 16tk; 25mg 14tk; 25mg 10tk; 25mg 20tk; 25mg 56tk; 25mg 30tk; 25mg 5tk; 25mg 7tk
promethazine caduceus õhukese polümeerikattega tablett
caduceus pharma ltd. - prometasiin - õhukese polümeerikattega tablett - 50mg 5tk; 50mg 20tk; 50mg 10tk; 50mg 16tk; 50mg 30tk; 50mg 14tk; 50mg 8tk; 50mg 56tk
dimedrol süstelahus
north china pharmaceutical group corp. imp&exp.co.ltd. - difenhüdramiin - süstelahus - 10mg 1ml 1ml 10tk
calcii gluconas süstelahus
north china pharmaceutical group corp. imp&exp.co.ltd. - kaltsiumglükonaat - süstelahus - 100mg 1ml 10ml 10tk
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - tsüstiline fibroos - muud hingamisteede tooted - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
amphotericin b 50mg süstelahuse pulber
north china pharmaceutical group corp. imp&exp.co.ltd. - amfoteritsiin - süstelahuse pulber - 50mg 1tk
buccolam
neuraxpharm pharmaceuticals s.l. - midasolaam - epilepsia - psühhoeptikumid - ravi pikaajaline, äge, convulsive krambid imikutel, väikelastel, lastel ja noorukitel (alates kolme kuu jooksul vähem kui 18 aastat). buccolam tuleb kasutada ainult vanemate / hooldajate kui patsiendil on diagnoositud, et on epilepsia. imikute vahel, kolme ja kuue kuu vanusest, tuleb ravi haigla tingimustes, kus järelevalve on võimalik ja taaselustuse seadmed on saadaval.
elaprase
takeda pharmaceuticals international ag ireland branch - idursulfaas - mukopolüsahhariidoos ii - muud alimentary seedetrakti ja ainevahetust tooted, - elaprase on näidustatud hunteri sündroomiga (mukopolüsahhariidoos ii, mps ii) patsientide pikaajaliseks raviks. kliinilistes uuringutes ei uuritud heterosügootseid emasid.
firmagon
ferring pharmaceuticals a/s - degareliks - eesnäärmevähk - endokriinset ravi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.